Literature DB >> 22118808

Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder.

Boadie W Dunlop1, Mary E Kelley, Tanja C Mletzko, Cristina M Velasquez, W Edward Craighead, Helen S Mayberg.   

Abstract

Previous studies suggest that individual preferences for medication- or psychotherapy-based treatments for depression may affect outcomes in clinical trials that compare these two forms of treatment. We assessed patients' beliefs about the causes of their depression, their preferred treatment, and strength of that preference in 80 patients participating in a 12-week clinical trial evaluating neuroimaging predictors of response to cognitive behavior therapy (CBT) or escitalopram. Forty-five patients expressed a preference for one of the 2 treatments, but being matched to preference did not influence remission or completion rates. Medication-preferring patients were more likely to terminate the trial early, regardless of treatment received. CBT-preferring patients rarely endorsed unknown causes for their depression, and medication-preferring patients were highly unlikely to identify pessimistic attitudes as a source of their depression. Among patients willing to be randomized to treatment, preference does not appear to strongly influence outcome. Specific preferences for CBT or medication may reflect differing conceptualizations about depressive illness, knowledge of which may enhance treatment retention and efficacy.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22118808      PMCID: PMC3288535          DOI: 10.1016/j.jpsychires.2011.11.003

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  39 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  Treatment preferences affect the therapeutic alliance: implications for randomized controlled trials.

Authors:  Brian M Iacoviello; Kevin Scott McCarthy; Marna S Barrett; Moira Rynn; Robert Gallop; Jacques P Barber
Journal:  J Consult Clin Psychol       Date:  2007-02

3.  The impact of client treatment preferences on outcome: a meta-analysis.

Authors:  Joshua K Swift; Jennifer L Callahan
Journal:  J Clin Psychol       Date:  2009-04

4.  Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression.

Authors:  Mark D Sullivan; Wayne J Katon; Joan E Russo; Ellen Frank; James E Barrett; Thomas E Oxman; John W Williams
Journal:  J Am Board Fam Pract       Date:  2003 Jan-Feb

5.  Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms.

Authors:  C Chilvers; M Dewey; K Fielding; V Gretton; P Miller; B Palmer; D Weller; R Churchill; I Williams; N Bedi; C Duggan; A Lee; G Harrison
Journal:  BMJ       Date:  2001-03-31

6.  Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients' choice arm.

Authors:  Ulrich Hegerl; Martin Hautzinger; Roland Mergl; Ralf Kohnen; Michael Schütze; Winfried Scheunemann; Antje-Kathrin Allgaier; James Coyne; Verena Henkel
Journal:  Int J Neuropsychopharmacol       Date:  2009-04-03       Impact factor: 5.176

7.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

8.  Patients' explanations for depression: a factor analytic study.

Authors:  Rick Budd; Darren James; Ian Hughes
Journal:  Clin Psychol Psychother       Date:  2008 Jan-Feb

9.  Assessing patient beliefs in a clinical trial of Hypericum perforatum in major depression.

Authors:  Carla M Bann; Corette B Parker; Jacques Bradwejn; Jonathan R T Davidson; Benedetto Vitiello; Kishore M Gadde
Journal:  Depress Anxiety       Date:  2004       Impact factor: 6.505

10.  Patients' depression treatment preferences and initiation, adherence, and outcome: a randomized primary care study.

Authors:  Patrick J Raue; Herbert C Schulberg; Moonseong Heo; Sibel Klimstra; Martha L Bruce
Journal:  Psychiatr Serv       Date:  2009-03       Impact factor: 4.157

View more
  26 in total

Review 1.  The role of depression pharmacogenetic decision support tools in shared decision making.

Authors:  Katarina Arandjelovic; Harris A Eyre; Eric Lenze; Ajeet B Singh; Michael Berk; Chad Bousman
Journal:  J Neural Transm (Vienna)       Date:  2017-10-29       Impact factor: 3.575

2.  Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.

Authors:  Boadie W Dunlop; Devon LoParo; Becky Kinkead; Tanja Mletzko-Crowe; Steven P Cole; Charles B Nemeroff; Helen S Mayberg; W Edward Craighead
Journal:  Am J Psychiatry       Date:  2019-02-15       Impact factor: 18.112

3.  A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression.

Authors:  Pim Cuijpers; Hisashi Noma; Eirini Karyotaki; Christiaan H Vinkers; Andrea Cipriani; Toshi A Furukawa
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

4.  Client preferences affect treatment satisfaction, completion, and clinical outcome: a meta-analysis.

Authors:  Oliver Lindhiem; Charles B Bennett; Christopher J Trentacosta; Caitlin McLear
Journal:  Clin Psychol Rev       Date:  2014-06-16

5.  Reconciling variable findings of white matter integrity in major depressive disorder.

Authors:  Ki Sueng Choi; Paul E Holtzheimer; Alexandre R Franco; Mary E Kelley; Boadie W Dunlop; Xiaoping P Hu; Helen S Mayberg
Journal:  Neuropsychopharmacology       Date:  2013-12-19       Impact factor: 7.853

6.  The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis.

Authors:  Lynn Boschloo; Ella Bekhuis; Erica S Weitz; Mirjam Reijnders; Robert J DeRubeis; Sona Dimidjian; David L Dunner; Boadie W Dunlop; Ulrich Hegerl; Steven D Hollon; Robin B Jarrett; Sidney H Kennedy; Jeanne Miranda; David C Mohr; Anne D Simons; Gordon Parker; Frank Petrak; Stephan Herpertz; Lena C Quilty; A John Rush; Zindel V Segal; Jeffrey R Vittengl; Robert A Schoevers; Pim Cuijpers
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

7.  Pretreatment brain states identify likely nonresponse to standard treatments for depression.

Authors:  Callie L McGrath; Mary E Kelley; Boadie W Dunlop; Paul E Holtzheimer; W Edward Craighead; Helen S Mayberg
Journal:  Biol Psychiatry       Date:  2013-12-19       Impact factor: 13.382

8.  A Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression.

Authors:  Stuart J Eisendrath; Erin Gillung; Kevin L Delucchi; Zindel V Segal; J Craig Nelson; L Alison McInnes; Daniel H Mathalon; Mitchell D Feldman
Journal:  Psychother Psychosom       Date:  2016-01-26       Impact factor: 17.659

9.  Toward a neuroimaging treatment selection biomarker for major depressive disorder.

Authors:  Callie L McGrath; Mary E Kelley; Paul E Holtzheimer; Boadie W Dunlop; W Edward Craighead; Alexandre R Franco; R Cameron Craddock; Helen S Mayberg
Journal:  JAMA Psychiatry       Date:  2013-08       Impact factor: 21.596

10.  The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons.

Authors:  Pim Cuijpers; Marit Sijbrandij; Sander L Koole; Gerhard Andersson; Aartjan T Beekman; Charles F Reynolds
Journal:  World Psychiatry       Date:  2013-06       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.